title: Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle.
authors.affiliation: Concord Hospital IBD Service, Sydney, New South Wales, Australia.
authors.forename: N
authors.identifier: 0000-0001-7771-5248
authors.initials: N
authors.lastname: Mitrev
authors.affiliation: Concord Hospital IBD Service, Sydney, New South Wales, Australia.
authors.forename: V
authors.initials: V
authors.lastname: Kariyawasam
authors.affiliation: Concord Hospital IBD Service, Sydney, New South Wales, Australia.
authors.forename: R W
authors.identifier: 0000-0001-5944-3488
authors.initials: RW
authors.lastname: Leong
mesh_terms: D000911:Antibodies, Monoclonal; D003424:Crohn Disease; D016903:Drug Monitoring; D005765:Gastrointestinal Agents; D006801:Humans; D000069285:Infliximab; D012003:Rectal Fistula; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab